Evidence map›Paper›PMID 24395571›Full record

ArticleMolecular medicine (Cambridge, Mass.)2014

Kisspeptin effect on endothelial monocyte activating polypeptide II (EMAP-II)-associated lymphocyte cell death and metastases in colorectal cancer patients.

Martha Stathaki, Athanasios Armakolas, Andreas Dimakakos, Loukas Kaklamanis, Ioannis Vlachos, Manoussos M Konstantoulakis, George Zografos, Michael Koutsilieris

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Martha StathakiFirst Propadeutic Surgical Clinic, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece Physiology Laboratory, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
Athanasios ArmakolasPhysiology Laboratory, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
Andreas DimakakosPhysiology Laboratory, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
Loukas KaklamanisDepartment of Pathology, Onasio Hospital, Athens, Greece.
Ioannis VlachosPhysiology Laboratory, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
Manoussos M KonstantoulakisFirst Propadeutic Surgical Clinic, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
George ZografosFirst Propadeutic Surgical Clinic, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
Michael KoutsilierisPhysiology Laboratory, Athens Medical School, National and Kapodestrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kisspeptin is an antimetastatic agent in some cancers that has also been associated with lymphoid cell apoptosis, a phenomenon favoring metastases. Our aim was to determine the association of kisspeptin with lymphocyte apoptosis and the presence of metastases in colorectal cancer patients. Blood was drawn from 69 colon cancer patients and 20 healthy volunteers. Tissue specimens from healthy and pathological tissue were immunohistochemically analyzed for kisspeptin and endothelial monocyte activating polypeptide II (EMAP-II) expression. Blood EMAP-II and soluble Fas ligand (sFasL) levels were examined by an enzyme-linked immunosorbent assay method. The kisspeptin and EMAP-II expression and secretion levels in the DLD-1 and HT-29 colon cancer cell lines were examined by quantitative real-time polymerase chain reaction, Western analysis and enzyme-linked immunosorbent assay, whereas lymphocyte viability was assessed by flow cytometry. The effect of kisspeptin on the viability of colon cancer cells was examined by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. Exogenous, synthetic and naturally produced, kisspeptin induces through the G-protein-coupled receptor 54 (GPR54; also known as the kisspeptin receptor) the EMAP-II expression and secretion in colon cancer cell lines, inducing in vitro lymphocyte apoptosis, as verified by the use of an anti-EMAP-II antibody. These results were reversed with the use of kisspeptin inhibitors and by kisspeptin-silencing experiments. Tumor kisspeptin expression was associated with the tumor EMAP-II expression (p < 0.001). Elevated kisspeptin and EMAP-II expression in colon cancer tissues was associated with lack of metastases (p < 0.001) in colon cancer patients. These data indicate the antimetastatic effect of tumor-elevated kisspeptin in colon cancer patients that may be mediated by the effect of kisspeptin on EMAP-II expression in colon cancer tumors in patients with normal serum EMAP-II levels. These findings provide new insight into the role of kisspeptin in the context of metastases in colon cancer patients.

Indexed as

AgedAged, 80 and overApoptosisCell Line, TumorCell SurvivalColorectal NeoplasmsCytokinesGene SilencingHumansKisspeptinsLymphocytesMiddle AgedNeoplasm ProteinsReceptors, G-Protein-CoupledReceptors, Kisspeptin-1RNA-Binding ProteinsCytokinesKISS1 protein, humanKISS1R protein, humanKisspeptinsNeoplasm ProteinsReceptors, G-Protein-CoupledReceptors, Kisspeptin-1RNA-Binding Proteinssmall inducible cytokine subfamily E, member 1

Identifiers

PMID24395571
PMCPMC3960398
OpenAlexW2108128561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.